These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18436722)

  • 21. Making advances in first-line chronic lymphocytic leukemia treatment.
    Wierda WG
    J Clin Oncol; 2012 Sep; 30(26):3162-4. PubMed ID: 22869876
    [No Abstract]   [Full Text] [Related]  

  • 22. Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine.
    Eichbaum M; Bischofs E; Nehls K; Schneeweiss A; Sohn C
    Drugs Today (Barc); 2009 Jun; 45(6):431-44. PubMed ID: 19649333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
    [No Abstract]   [Full Text] [Related]  

  • 24. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
    Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
    Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
    García-Muñoz R; García DK; Roldán-Galiacho V; Merchante-Andreu M; Campeny-Najara A; Rabasa P
    Ann Hematol; 2014 Apr; 93(4):699-702. PubMed ID: 23907409
    [No Abstract]   [Full Text] [Related]  

  • 26. Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
    Montillo M; Tedeschi A; Gaidano G; Coscia M; Petrizzi VB; Orlandi E; Cascavilla N; Ghia P; Motta M; Gallamini A; Frustaci AM; Rossi D; De Paoli L; Nichelatti M; Morra E; Massaia M
    Haematologica; 2014 Sep; 99(9):e159-61. PubMed ID: 24972768
    [No Abstract]   [Full Text] [Related]  

  • 27. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bendamustine: a new therapeutic option for hematologic malignancies.
    Cheson BD
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
    [No Abstract]   [Full Text] [Related]  

  • 29. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
    Niederle N; Megdenberg D; Balleisen L; Heit W; Knauf W; Weiß J; Freier W; Hinke A; Ibach S; Eimermacher H
    Ann Hematol; 2013 May; 92(5):653-60. PubMed ID: 23340738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ofatumumab approved for advanced CLL.
    Traynor K
    Am J Health Syst Pharm; 2009 Dec; 66(23):2062. PubMed ID: 19923303
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).
    Shoji J; Lew SQ
    BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Toxicodermia by bendamustine: development of a desensization protocol].
    Sangrador Pelluz C; Luis Hidalgo MM; Martínez García M; Pérez-Serrano Lainosa MD; Soler Company E
    Farm Hosp; 2013; 37(5):421-3. PubMed ID: 24128107
    [No Abstract]   [Full Text] [Related]  

  • 33. Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
    Lalic H; Aurer I; Batinic D; Visnjic D; Smoljo T; Babic A
    Oncol Rep; 2022 Jun; 47(6):. PubMed ID: 35506458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Huge kidneys in a patient with chronic lymphocytic leukaemia.
    Esposito P; Libetta C; Rampino T; Gregorini M; Margiotta E; Dal Canton A
    Br J Haematol; 2015 Feb; 168(4):470. PubMed ID: 25384540
    [No Abstract]   [Full Text] [Related]  

  • 35. Obinutuzumab approved for CLL: Monoclonal antibody product is first FDA-approved breakthrough therapy.
    Traynor K
    Am J Health Syst Pharm; 2013 Dec; 70(24):2162. PubMed ID: 24296835
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
    Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
    J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
    Ujjani C; Cheson B
    Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia.
    Small S
    Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628
    [No Abstract]   [Full Text] [Related]  

  • 39. Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine.
    Bartel C; Obermüller N; Rummel MJ; Geiger H; Hauser IA
    Clin Nephrol; 2008 Apr; 69(4):285-9. PubMed ID: 18397703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
    Köppler H; Fuss H; Hurtz HJ; Knigge O; Losem C; Reschke D; Schmitz S; Weide R; Weiß J; Hallek M;
    Br J Haematol; 2012 Jul; 158(2):238-241. PubMed ID: 22571691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.